Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jie Biao Qing Li (also referred to as Jiebiaoqingli Recipe or Granules) is a Traditional Chinese Medicine (TCM) herbal formula primarily developed and studied by the China-Japan Friendship Hospital for the treatment of respiratory viral infections. The formula is based on the TCM therapeutic principle of "releasing the exterior" to resolve surface symptoms like fever and "clearing the interior" to address internal heat and inflammation. It has been evaluated in clinical trials for its efficacy in treating influenza, where it was compared against oseltamivir, and has been used as part of integrative treatment protocols for severe COVID-19. The formula is sometimes associated with or identified as the classic Ma Xing Shi Gan decoction, which typically consists of Ephedra, Apricot Kernel, Gypsum, and Licorice, though specific hospital-prepared versions may vary.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jiebiaoqingli recipe.